1401731-36-9

Basic information

• Product Name: 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one
• Synonyms: 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one
• CAS NO: 1401731-36-9
• Molecular Weight: 385.428
• Mol File: 1401731-36-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one(1401731-36-9)
• EPA Substance Registry System: 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one(1401731-36-9)

Safety Data

• Hazardous Substances Data: 1401731-36-9(Hazardous Substances Data)

Upstream product

• 1401732-44-2 1-(3-((6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1111638-43-7 1-(4-methoxybenzyl)-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine 
• 1401732-43-1 1-(3-((6-chloropyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1111638-42-6 5-bromo-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 885223-65-4 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1186608-73-0 3-methyl-1H-pyrazolo[3,4-b]pyridin-5-amine 
• 62908-83-2 3-methyl-5-nitropyrazolo<3,4-b>pyridine 
• 31992-43-5 1-(3-aminophenyl)pyrrolidin-2-one 

Relevant articles and documents

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.